Page 1,636«..1020..1,6351,6361,6371,638..1,6501,660..»

SGMC Diabetes Management Center Hosting Free Grocery Store Tour Monday Night – ValdostaToday.com

Posted: March 20, 2017 at 5:41 pm


ValdostaToday.com
SGMC Diabetes Management Center Hosting Free Grocery Store Tour Monday Night
ValdostaToday.com
VALDOSTA Approximately 1,121,495 people in Georgia, or 14.2% of the adult population, have diabetes, according to the American Diabetes Association. Every year an estimated 60,000 people in Georgia are diagnosed with diabetes. Staying healthy ...
Diabetes support group heads to the grocery store for lessonWALB-TV

all 2 news articles »

See the original post:
SGMC Diabetes Management Center Hosting Free Grocery Store Tour Monday Night - ValdostaToday.com

Posted in Diabetes | Comments Off on SGMC Diabetes Management Center Hosting Free Grocery Store Tour Monday Night – ValdostaToday.com

State-of-art new clinic – and vets – The Dickinson Press

Posted: March 19, 2017 at 4:42 pm

West was part of a team a few years ago at Kansas State University that used maggots. The maggots ate the dead flesh out of a horse's hoof. With that and stem cells and surgery, they saved a severely lame mare from euthanasia.

And then there's West River's other veterinarian from the millennial generationJenna Innes, 31, who has been practicing at West River for about two years.

Innes recalled examining an extremely thin dog that couldn't put on weight. Its owner told Innes they had tried to find help elsewhere but the problem hadn't been successfully diagnosed and making it worse, people, suspecting the owner of animal neglect, had even reported the situation to authorities.

It was Innes who was able to figure out what was wrong an odd pancreatic disorder and successfully treated it. The dog is now teetering on being too pudgy, Innes said.

Innes and West, the clinic's two newest and youngest vets, "bring youth and energy, new technologies and information," said Dr. Ethan Andress, who has practiced at the clinic for about 17 years.

"They are two very talented veterinarians that have an energy and passion for what they do...the next generation to take over the clinic," Andress said.

In addition, they and the clinic's other three vets get to practice in a new state-of-the-art facility with such equipment as a digital x-ray machine and in-house blood machines that give immediate results for most tests.

An open house to celebrate the clinic's one-year anniversary is set for April 21.

The new clinic, at 203 Highway 12 E., is located across town from the old clinic, which is now being used for boarding and storage, West said.

West, whose strongest interest is equine medicine, said the clinic is seeing a doubling in recent years on time spent providing equine services.

West also has started Ferrier Days at the clinic bringing in ferrier Casey Kalenze from Bowman to provide services. While there, horses can also get other services deworming, vaccinations, exams.

"It's a convenience, saves (the horse owners) mileage," West said.

She's also considering adding alternative treatments such as acupuncture and chiropractic help.

Innes, who grew up on a sheep and cattle ranch, has a general practice, but because of her background has become the go-to vet for the clinic's sheep and goat clients.

"I get phone calls from all across the state," she said.

Innes, who grew up in Wyoming on the family ranch, said her family knew tough times.

"We were pretty broke," said Innes, who was age 12 when her dad died.

So she said she knows how hard it is sometimes financially to call a vet in to help.

The West River veterinarians say they are aware that many pet owners and livestock producers have a limited budget.

"We do as much as we can...We can come up with creative solutions," West said. "We can do a lot of good even within a limited budget.

Innes said she knows personally the impact of one sick animal: "I remember how much that one cow can affect the family. That's a person's livelihood."

Innes said she wanted to be a veterinarian from the moment she knew what the word meant.

"I always wanted to save animals...I always wished I could help," Innes said.

She said she remembers regularly bringing homeless animals home and caring for them, sometimes in secret locations, unbeknownst to the family.

"My parents kind of got used to it," she said.

Innes, a graduate of Auburn University's vet school in Alabama, said she made it through the extremely rigorous program not because she's a genius, but because, "I'm a really hard worker."

She said she kind of lives by something she read once: "If you're lucky enough to find a way of life you love, you have to find the courage to live it."

Innes, who wanted to come back close to home to practice, convinced a vet at West River to be her preceptor for her vet school's required two-month work clinic she had to complete.

The clinic would end up offering her a position.

Now she cares for everything from sheep, goats, cattle, dogs, to sugar gliders and ferrets. She once had to break the news to someone who thought they had bought two male guinea pigs that the one getting "fat" was definitely not male.

West grew up in Menoken in a rodeo family.

West said her parents recall that since she was tiny she was forever talking about becoming a veterinarian.

"I loved working with and helping animals...especially liked working with horses," West said in a recent interview.

As an undergraduate pursuing a microbiology degree at North Dakota State University, she and her quarter horse, Henry, competed on the school's rodeo club in team roping, and she maintained her violin playing by performing with a group at nearby Concordia College in Minnesota.

Later at Kansas State University's vet school, she worked toward an expertise in equine medicine and surgery.

She said she always planned to come back to North Dakota, but worked in Iowa for a time while her husband, a chemical engineer, had a position there.

He has since left that career, getting back into ranching at his grandparents' place north of Hettinger where the couple and their daughter, age 1, now live.

West said it was during vet school that she became familiar with the West River clinic. For needed college credits she worked at West River for a two-week unpaid externship. When one of the vets, Dr. Donald Safratowich retired, she was contacted about taking his place.

While a main focus is doctoring horses, she also works on every other type animal that walks in or is carried in: About every week they get animals that have been hit by cars or tractors and a lot by ATVS, she said.

Going out in the field, West and Innes have experienced hesitancy from some livestock producers when they show up.

"They'll ask, 'Where's one of the guys?'" Said West, who is 5 foot 3 inches tall.

But she said after they observe her at work, the outcomes, everything's fine.

"You do one job for them and they see you really know what you're doing and it's not an issue any longer," she said.

Innes said clients who are reluctant to accept a female vet are her favorite clients.

"I love clients like that. I make it my goal to win them over...prove myself," Innes said.

Innes said she has natural advantages like her small hands. She said ranchers have express how they wished they could do what she does.

With her small hands and arms she has an easier time getting in to help the mama cows, plus she has the tools and various techniques to make the job easier.

"More than nine times out of 10 they'll (the ranchers) end up saying, 'You're OK,' " Innes said.

But she said she also understands their attitudes: "My grandfather was an old-school rancher."

She said one thing that surprised her about being a veterinarian was the "compassion fatigue." She said from growing up on a ranch she knows it's expected that animals die, sometimes. It's understood and dealt with.

But when she as a vet can't save an animal like a past case, a dog that after five hours of surgery couldn't be saved that's tough.

"We care so much... I don't know if people realize how much we can take home," she said.

Innes said clinic's veterinarians are more than happy to and do take phone calls and questions from the general public about anything, from vaccination questions to whatever.

Innes said she is so proud to work at this state-of-the-art facility a 12,300-square-foot building on nine acres and hopes people will come to the open house April 21 to see it.

"We have some of the best medical equipment," she said.

And it's a team effort.

She said the veterinarians decided to have one group office in the new building instead of individual offices for each vet. That way, they sit together and discuss cases as a group. Sometimes, an x-ray is analyzed by more than one set of eyes.

"You get your money's worth...five vets for the price of one," Innes said.

Actually, 5.5 vets, because the retiree still comes in to help, she said.

The clinic's other vets besides Innes, West and Andress are Lisa Henderson, Bleaux Johnson and part-time help from longtime veterinarian Dr. Donald Safratowich, who is retired, sort of.

The rest is here:
State-of-art new clinic - and vets - The Dickinson Press

Posted in Alabama Stem Cells | Comments Off on State-of-art new clinic – and vets – The Dickinson Press

Puma Biotechnology Inc (NYSE:PBYI) Impact Score At 0 – Stock Observer

Posted: March 19, 2017 at 4:42 pm

Puma Biotechnology Inc (NYSE:PBYI) daily sentiment score is -0.018 for articles printed on 2017-03-18. This is on a -1-1 scale after assessing the buzzing news and its impact on the system. The assessment is hooked on the dependable web sources.

Bullish target is at $89 while conservative price target is $72 on respective equity.

Puma Biotechnology Inc has an ABR of 1.67. The stock rating was 1.67 in preceding quarter. Financial numbers can be released on 2017-05-09. Consensus estimated EPS is $-1.88 for this quarter.

Securities prices are motivated by fundamentals in both the controlled and open street. Informed or not, shareholders weightage is on fiscals and other allied valuation basics. The metrics under contemplation are per-share earnings and associated ratios. Investors shift their emphasis on comprehensive financial report. Also, they predict miscellaneous components, which consists the reserves and other firm resources and also its valuation to due debt. Definitely, it is an unusual exercise to assess and measure all features while generating funds in equity market. A disciplined appraisal bodes well when the notion is to contribute a fair part in planned income.

Whatever ratings Zacks gives can to some degree exhibit variance from calls of First Call. Both the entities dont poll same set of street analysts, and as a result the projections vary. Puma Biotechnology Inc (NYSE:PBYI) posted EPS of $-2.04 for period closed on 2016-12-31. The reported number was $-0.02 off from the consensus. In percentage terms variance was -0.99%.

More here:
Puma Biotechnology Inc (NYSE:PBYI) Impact Score At 0 - Stock Observer

Posted in Biotechnology | Comments Off on Puma Biotechnology Inc (NYSE:PBYI) Impact Score At 0 – Stock Observer

Lactate may be key for cancer development – Medical News Today

Posted: March 19, 2017 at 4:41 pm

Researchers are working hard to understand the mechanism responsible for oncogenesis, the process through which normal cells become cancerous ones. A new study focuses on lactate - a molecule produced during intense exercise - and explains its role in cancer cell formation.

New research, published in the journal Carcinogenesis, analyzes the role of lactate in oncogenesis.

Lactate is a byproduct of the chemical process known as glycolysis - the breaking down of sugar, or glucose, into smaller molecules with the purpose of producing energy. During intense physical activity, lactate accumulates in the tissue and blood, which can sometimes lead to poorer physical performance and muscle stiffness.

At the beginning of the 20th century, German scientist Otto Warburg noticed that cancer cells consume a lot more glucose than normal cells. The so-called Warburg effect refers to the fact that cancer cells undergo more glycolysis and produce more lactate compared with normal cells.

The new research - led by Inigo San Millan, director of the Sports Performance Department and physiology laboratory at the University of Colorado-Boulder's Sports Medicine and Performance Center - set out to understand why the Warburg effect happens. Since Warburg's time, the focus in cancer research has shifted from cell metabolism to genetics, but the new paper hopes to put lactate back at the center of cancer research.

San Millan and colleagues suggest that the molecule is "the only metabolic compound involved and necessary" in the five stages that follow on from carcinogenesis.

The study examines the role of lactate in angiogenesis (the process by which new blood vessels form inside the tumors), immune escape (the cancer cells' ability to elude the body's immune response), and cell migration, as well as in metastasis and self-sufficient metabolism.

The paper explains how in metastasis, lactate helps to create an acidic microenvironment outside the cancer cell, which supports the spread of cancer cells.

Finally, the study also explores the link between lactate and genetic components. The researchers hypothesize that a triad of transcription factors commonly found in most cancers - HIF-1, cMYC, and p53 - also triggers and perpetuates lactate deregulation.

The crucial role of lactate in cancer cell formation may explain why people who exercise regularly are at a lower risk of developing cancer. In athletes and those who work out, the body is trained to efficiently turn lactate into an energy source for the body, thus stopping it from accumulating in excess.

Based on their findings, the researchers speculate that a sedentary lifestyle, combined with too much sugar in our diets, may lead to an excessive accumulation of lactate, thus setting the stage for cancer.

"With this paper, we open a whole new door for understanding cancer, showing for the first time that lactate is not only present, but mandatory for every step in its development."

Inigo San Millan

In the near future, San Millan will collaborate with the University of Colorado Hospital to study the effect of tailored exercise programs on cancer patients. The researcher is already studying breast cancer cell lines.

San Millan hopes that, eventually, his research will help to develop drugs that stop the lactate from accumulating. "We hope to sound the alarm for the research community that to stop cancer you have to stop lactate," he says. "There are many ways to do that," such as by targeting monocarboxylate transporters, which ferry lactate from cell to cell.

Learn how vitamin C can target and kill cancer stem cells.

View post:
Lactate may be key for cancer development - Medical News Today

Posted in Cell Medicine | Comments Off on Lactate may be key for cancer development – Medical News Today

3 women blinded after undergoing unproven stell cell ‘therapy’ – WZZM13.com

Posted: March 19, 2017 at 4:41 pm

April Stevens , WZZM 12:08 PM. EST March 19, 2017

Close up of an eye surgery, stock image. (Photo: Thinkstock)

SANFORD, CALIF. - Three women with macular degeneration were blinded after an unproven stem cell treatment described as a "clinical trial."

A recent paper published in The New England Journal of Medicine documents the cases and is a "call to awareness for patients, physicians and regulatory agencies" on minimally regulated, patient-funded research according to Jeffrey Goldberg, MD, PhD, professor and chair of ophthalmology at the Stanford University School of Medicine and co-author of the paper.

Three patients -- all women ranging in age from 72 to 88 -- suffered from macular degeneration, a common disease of the retina that leads to loss of vision over time. Before the patients underwent surgery, their vision ranged from 20/30 to 20/200.

Now, all three patients are likely to remain blind due to complications from the stem cell treatments.

"Although I can't say it's impossible, it's extremely unlikely they would regain vision," said co-author Thomas Albini, MD,an associate professor of clinical ophthalmology at the University of Miami, where two of the patients went to treat complications.

The trial appealed to patients 'desperate for care'

Two of the patients learned of the so-called clinical trial on ClinicalTrials.gov, a registry and results database run by the U.S. National Library of Medicine. The patients believed they were participating in a trial, although the consent form and other written materials given to the them did not mention a trial, Albini said.

"There's a lot of hope for stem cells, and these types of clinics appeal to patients desperate for care who hope that stem cells are going to be the answer, but in this case these women participated in a clinical enterprise that was off-the-charts dangerous," Albini said.

Each patient paid $5,000 for the procedure, which authors said should have raised a red flag.

"I'm not aware of any legitimate research, at least in ophthalmology, that is patient-funded," Albini said.

At the Florida clinic where the procedure took place, patients have fat cells removed from their abdomens and a standard blood draw. The fat tissue was processed in a lab with the goal of obtaining stem cells and platelet-dense plasma was isolated from the blood. The cells were then mixed with the plasma and then injected into their eyes.

Patients reported that the entire process took less than an hour. The patients had both eyes treated at once -- another red flag, Albini and Goldberg said, because most doctors would opt to see how one eye responds to an experimental treatment before attempting the other eye.

No evidence the procedure would have restored vision

Shoddy stem cell preparation may have led to some of the complications, Albini said. However, even if executed correctly, there is no evidence that the procedure could have help to restore vision both authors report.

There is sparse evidence that fat-derived stem cells, the kind that the clinic claimed to use, are capable of differentiating, or maturing, into the kind of cells that researchers are attempting to target to develop therapies that could slow down macular degeneration.

"There is a lot of very well-founded evidence for the positive potential of stem therapy for many human diseases, but there's no excuse for not designing a trial properly and basing it on preclinical research," Goldberg said.

The "trial" lacked nearly all of the components of a properly designed clinical trial, including a hypothesis based on laboratory experiments, assignment of a control group and treatment group, collection of data, masking of clinical and patient groups, and plans for follow-up, Goldberg and Albini said.

Listings on ClinicalTrials.gov are not fully scrutinized for scientific soundness, Goldberg said. Although still visible on the website, the listing now states: "This study has been withdrawn prior to enrollment."

Albini says the clinic is also no longer performing these eye injections, but still seeing patients.

The procedures were not subject to Food and Drug Administration approval because the cells were not transferred between patients and were considered "minimally processed," according to Title 21, Part 1271.10, of the Code of Federal Regulations. The FDA released more specific guidelines in October 2015, after these procedures were performed, establishing the requirement for FDA oversight and approval for these types of procedures.

'Lack of oversight can lead to bad players and bad outcomes'

"We expect health care providers to take every precaution to ensure patient safety, but this definitely shows that the lack of oversight can lead to bad players and bad outcomes. It's alarming," Albini said.

The authors acknowledged that it is difficult for patients to know whether a clinical trial, or a stem cell therapy, is legitimate. Goldberg recommended that patients considering a stem cell treatment consult a website, A Closer Look at Stem Cells, run by the International Society for Stem Cell Research and to check if the trial is affiliated with an academic medical center.

More information about this paper can be found here. You can read the paper here.

Makeit easy to keep up to date with more stories like this.Download theWZZM13 app now.

April Stevensis a multi-platform producer. Have a news tip? Emailnews@wzzm13.com, visit ourFacebook pageorTwitter.

2017 WZZM-TV

See the rest here:
3 women blinded after undergoing unproven stell cell 'therapy' - WZZM13.com

Posted in Cell Therapy | Comments Off on 3 women blinded after undergoing unproven stell cell ‘therapy’ – WZZM13.com

Stem cell therapy helps patients with osteoarthritis – Palm Beach Post – Palm Beach Post

Posted: March 19, 2017 at 4:41 pm

New treatments and advances in research are giving new hope to people affected by Osteoarthritis pain and symptoms. Dr. Theofilos provides stem cell therapy for osteoarthritis to help those achieve better health and live life in motion.

Stem cell therapy for osteoarthritis is being studied for efficacy in improving the complications in patients through the use of their own stem cells. These procedures may help patients who dont respond to typical drug treatment, want to reduce their reliance on medication, or are looking to try stem cell therapy due to pain or discomfort.

Osteoarthritis, also known as degenerative arthritis or degenerative joint disease, is a group of mechanical abnormalities involving degradation of joints, including articular cartilage and subchondral bone. Symptoms may include joint pain, tenderness, stiffness, locking and sometimes an effusion. When bone surfaces become less well protected by cartilage, bone may be exposed and damaged. As a result of decreased movement secondary to pain, regional muscles may atrophy, and ligaments may be affected.

Stem cell treatment is designed to target these areas within the joints to help with the creation of new cartilage cells. Mesenchymal stem cells are multipotent and have the ability to differentiate into cartilage called (chondrytes). The goal of each stem cell treatment is to inject the stem cells into the joint to create cartilage.

Its expected that results of the therapy will vary depending upon the many factors of the severity, patients overall health, nutritional state and immune function. Stem cell therapy is safe and effective in reducing pain and improving function for many patients.

Voted as one of America's Top Surgeons, Charles S. Theofilos, MD, Neurosurgeon and Founder of The Spine Center is a leading provider of the state-of-the-art, most comfortable and effective surgical, minimally invasive and non-surgical treatment options for a full range of cervical and spinal ailments, including stem cell therapy and artificial disc replacement. He was among a field of 20 top neuro and orthopedic surgeons in the U.S. chosen to participate in the groundbreaking Artificial Disc Study, which compared the clinical outcome of disc replacement versus traditional spinal fusion. A widely sought after educator and lecturer, Dr. Theofilos has offices in Palm Beach Gardens and Port St. Lucie.

_______________________________________________________________

11621 Kew Gardens Ave., Suite 101; Palm Beach Gardens

*In an effort to maintain and honor the commitment to our patients, we will continue to accept Medicare and Medicare Advantage insurance plans for all new and follow up appointments.

See the original post here:
Stem cell therapy helps patients with osteoarthritis - Palm Beach Post - Palm Beach Post

Posted in Cell Therapy | Comments Off on Stem cell therapy helps patients with osteoarthritis – Palm Beach Post – Palm Beach Post

Cutting-edge stem cell therapy proves safe, but will it ever be effective? – Science Magazine

Posted: March 19, 2017 at 4:41 pm

Masayo Takahashi (second from left) treated macular degeneration with retinal tissue grown from iPS cells.

Kyodo News/Contributor/getty images

By Dennis NormileMar. 15, 2017 , 5:00 PM

Its official: The first use of induced pluripotent stem (iPS) cells in a human has proved safe, if not clearly effective. Japanese researchers reported in this weeks issue of The New England Journal of Medicine (NEJM) that using the cells to replace eye tissue damaged by age-related macular degeneration (AMD) did not improve a patients vision, but did halt disease progression. They had described the outcome at conferences, but publication of the details is an encouraging milestone for other groups gearing up to treat diseased or damaged organs with the versatile replacement cells, which are derived from mature tissues.

This initial success is pretty momentous, says Alan Trounson, a stem cell scientist at the Hudson Institute of Medical Research in Melbourne, Australia. But the broader picture for iPS therapies is mixed, as researchers have retreated from their initial hopes of creating custommade stem cells from each patients tissue. That strategy might have ensured that recipients immune systems would accept the new cells. But it proved too slow and expensive, says Shinya Yamanaka of Kyoto University in Japan, who first discovered how to create iPS cells and is a co-author of the NEJM paper. He and others are now developing banks of premade donor cells. Using stocks of cells, we can proceed much more quickly and cost effectively, he says.

Even so, clinical work is progressing more quickly than I had expected, says Yamanaka, who did his groundbreaking work just a decade ago. His collaborator on this trial, Masayo Takahashi of the RIKEN Center for Developmental Biology in Kobe, Japan, had a head start. An ophthalmologist, Takahashi was familiar with the ravages of AMD, a condition that progressively damages the macula, the central part of the retina, and is the leading cause of blindness in the elderly.

Takahashi started investigating treatments for AMD in 2000, a time when the only cells capable of developing into all the tissues of the body had to be extracted from embryos. But she was stymied by immune reactions to these embryonic stem (ES) cells. When Yamanaka announced that he could induce mature, or somatic cells, to return to an ES celllike state, Takahashi quickly changed course to develop a treatment based on iPS cells.

Her team finally operated on the first patient, a 77-year-old Japanese woman with late-stage AMD, in September 2014. They took a sample of her own skin cells, derived iPS cells, and differentiated them into the kind of retinal cells destroyed by the disease. A surgeon then slipped a small sheet of the cells into the retina of her right eye.

An operation on a second patient was called off because a number of minor genetic mutations had crept into his iPS cells during processing, and uncontrolled growthcancerhas been a worry with such cells. These changes do not directly induce cancer, but we wanted to make safety the first priority, Yamanaka says. Also, Takahashi says, AMD drugs had stabilized the patients condition so there was no urgency in subjecting him to the risks of surgery, which include hemorrhaging and retinal damage.

Immediately after surgery the first patient reported her eyesight was brighter. Takahashi says the surgery halted further deterioration of her eye, even without the drug injections still being used to treat her other eye, and there were no signs of rejection of the graft as of last December.

Clinical work is progressing much more quickly than I expected.

The result is a proof of principle that iPS cellbased therapy is feasible, says Kapil Bharti, a molecular cell biologist at the U.S. National Institutes of Healths National Eye Institute in Bethesda, Maryland, who is also developing iPS cells for treating AMD. Takahashi says once her team gains more experience with the technique they will extend it to patients with earlier-stage AMD in an effort to preserve vision.

Last month, Takahashi won approval to try the procedure on another five patients with late-stage AMD. But this time, instead of using iPS cells derived from each patient, the team will draw on banked cells from a single donor. It takes time to create iPS cells, and a lot of time for the safety evaluation, Yamanaka says. It is also costly, at nearly $900,000 to develop and test the iPS cells for the first trial, Takahashi adds.

Using donor cells to create the iPS cells will make it more difficult to ensure immune compatibility. But Yamanaka says that donor iPS cells can be matched to patients based on human leukocyte antigen (HLA) haplotypessets of cell-surface proteins that regulate immune reactions. HLA-matched cells should require only small doses of immunosuppressive drugs to prevent rejection, Takahashi saysand perhaps none at all for transplantation into the immune-privileged eye.

Kyoto Universitys Center for iPS Cell Research and Application, which Yamanaka heads, has been developing an iPS cell bank. Just 75 iPS cell lines will cover 80% of the Japanese population through HLA matching, he says. Trounson, a past president of the California Institute for Regenerative Medicine, a stem cell funding agency, says banked iPS cells have advantages. Donor iPS cells may be safer than cells derived from older patients, whose somatic cells may harbor mutations. And Jordan Lancaster, a physiologist at the University of Arizona in Tucson, likes the speed of the approach. He is devising patches for heart failure patients based on iPS-derived myocardial cells that will be premanufactured, cryopreserved, and ready to use at a moments notice.

Patient-specific iPS cells will still have clinical uses. For one thing, Bharti says it will be difficult for cell banks to cover all HLA haplotypes. And a patients own iPS cells could be used to screen for adverse drug reactions, says Min-Han Tan, an oncologist at Singapores Institute of Bioengineering and Nanotechnology, who recently published a report on the approach.

Other human trials are not far behind. Yamanaka says his Kyoto University colleague Jun Takahashi (Masayo Takahashis husband) will launch trials of iPS-derived cells to treat Parkinsons disease within 2 years. Bharti hopes to start human trials of iPS cells for a different type of macular degeneration next year. And as techniques for making and growing iPS cells improve, researchers can contemplate treatments requiring not just 100,000 cells or sothe number in Takahashis retinal sheetsbut millions, as in Lancasters heart patches.

As clinical use approaches, Takahashi cautions that researchers need to keep public expectations realistic. For now, iPS treatments may help but wont fully reverse disease, she says. Regenerative medicine is not going to cure patients in the way they hope.

Please note that, in an effort to combat spam, comments with hyperlinks will not be published.

Go here to see the original:
Cutting-edge stem cell therapy proves safe, but will it ever be effective? - Science Magazine

Posted in Cell Therapy | Comments Off on Cutting-edge stem cell therapy proves safe, but will it ever be effective? – Science Magazine

U. scientists develop cell therapy for chronic disc pain – Deseret News

Posted: March 19, 2017 at 4:41 pm

SALT LAKE CITY Relief for chronic back and neck pain may be on the horizon, thanks to emerging science technology under development at the University of Utah.

Bioengineering researchers have discovered a technique to control chronic pain by regulating genes that reduce tissue- and cell-damaging inflammation.

This has applications for many inflammatory-driven diseases, said assistant professor Robby Bowles, who led the research. It could be applied for arthritis or to therapeutic cells that are being delivered to inflammatory environments that need to be protected from inflammation.

In laymens terms, the therapy has the potential to treat chronic pain by relieving swelling in affected areas and healing the tissue, he said.

For instance, chronic pain in slipped or herniated discs result from damaged tissue when swelling causes cells to create molecules that break down tissue, he explained. Inflammation is natures way of alerting the immune system to repair tissue or fight infection, but chronic inflammation can lead to tissue degeneration and pain, he said.

Bowles team uses the Clustered Regularly Interspaced Short Palindromic Repeat system known as CRISPR a new technology that modifies human genetics to halt cell death and keep cells from producing molecules that damage tissue and result in chronic pain, he said.

This is something that could be injected into your (damaged) discs to stop the signaling that is driving disc degeneration and the painful signaling, Bowles said. It would keep you from getting worse and it would stop the pain.

But Bowles said the therapy does not edit or replace genes, which is what CRISPR tools are typically used for. Instead, the therapy modulates the way genes turn on and off in order to protect cells from inflammation.

So they wont respond to inflammation. It disrupts this chronic inflammation pattern that leads to tissue degeneration and pain, he said. Were not changing what is in your genetic code. Were altering what is expressed. Normally, cells do this themselves, but we are taking engineering control over these cells to tell them what to turn on and turn off.

He said now that researchers know they can do this, doctors would be able to modify the genes using direct injection into the affected area which delays tissue degeneration. In the case of back pain, a patient may get a discectomy to remove part of a herniated disc to relieve the pain, but tissue near the spinal cord may continue to break down, leading to future pain, he said. This method could stave off additional surgeries by stopping the tissue damage, he noted.

The hope is that this stops degeneration in its tracks, and the patient could avoid any future surgeries, Bowles said. But its patient to patient. Some might still need surgery, but it could delay it.

So far, the team has developed a virus that can deliver the gene therapy and has filed for a patent on the system with the hope of moving to human trials after collecting initial data. One caveat Bowles noted was that there are currently no gene therapies approved for use by the U.S. Food and Drug Administration, so it may take some time to receive necessary acceptance.

So long term there are technological and regulatory hurdles to (overcome), he said. It could be about 10 years before this method is ready for use in patients.

Despite the regulatory issues, Bowles was optimistic about the long-range prospects for treating pain using this new therapy.

The CRISPR systems give us control that would allow us to begin treating these diseases in ways we couldnt treat them before, Bowles said. Over the next 10 to 15 years, were going to see a lot of these CRISPR technologies change these debilitating conditions.

The teams discovery was published in a new paper this month in a special issue of Tissue Engineering. The study was co-authored by University of Utah bioengineering doctoral student Niloofar Farhang and several other researchers in a collaborative project between the U., Duke University and Washington University in St. Louis.

Continue reading here:
U. scientists develop cell therapy for chronic disc pain - Deseret News

Posted in Cell Therapy | Comments Off on U. scientists develop cell therapy for chronic disc pain – Deseret News

Newer type 2 diabetes drugs show heart protective quality in study – Reuters

Posted: March 19, 2017 at 4:40 pm

By Bill Berkrot | WASHINGTON

WASHINGTON A newer class of type 2 diabetes drugs significantly cut the risk of death and hospitalization for heart failure compared with other medicines for the disease, according to data released on Sunday from a so-called real world study sponsored by AstraZeneca.

The drugs, known as SGLT-2 inhibitors, work by removing blood sugar via the urine and include Astra's Farxiga, Jardiance from Eli Lilly and Co and Boehringer Ingelheim, and Invokana from Johnson & Johnson.

Jardiance caused a stir in 2015, when a clinical trial conducted to reassure it does not cause heart problems instead showed it reduced the combined risk of hospitalization for heart failure or death from heart failure by 39 percent in high risk patients. The heart benefit has since been incorporated into Jardiance's label.

AstraZeneca is conducting its own large clinical trials to determine the heart effect of Farxiga with results expected in 2019.

But the latest data presented by Dr. Mikhail Kosiborod at the American College of Cardiology scientific meeting in Washington appears to indicate that heart protection is not limited to Jardiance.

"The fact that the results are remarkably consistent from country to country regardless of which compound predominates, that certainly seems to suggest that it's a class effect," said Kosiborod, a cardiologist from Saint Luke's Mid America Heart Institute in Kansas City. He noted that most Americans in the data were taking Invokana, while Farxiga was dominant in Europe.

The study, which analyzed data from more than 300,000 type 2 diabetes patients collected from six countries, found the SGLT-2 drugs slashed the combined risk of hospitalization for heart failure and death from any cause by 46 percent.

The data was obtained from real-world sources, such as medical records, claims databases and national registers.

Most patients were taking Farxiga or Invokana with less than 10 percent on Jardiance. The comparator medicines included a wide variety of diabetes treatments, including metformin, DPP-4 inhibitors, such as Merck & Co's Januvia, and insulin, among others.

The vast majority of patients had no history of heart disease. But heart disease is the number one killer of people with diabetes, and mounting evidence of heart protective qualities of SGLT-2 drugs could lead to greater use.

"This class has a real potential of improving patient outcomes," Kosiborod said.

Given the observational nature of the study the possibility of unmeasured confounding factors exists, researchers noted.

More than 400 million people worldwide have diabetes, of whom at least 90 percent have type 2.

(This story has been refiled to add word in last paragraph)

(Reporting by Bill Berkrot; Editing by Phil Berlowitz)

AUSTIN, Texas The size and width of a peacock's proud plumage attracts the gaze of males likely sizing up rivals and of females potentially looking for mates, a survey released on Wednesday showed.

WASHINGTON Fossils unearthed in India that are 1.6 billion years old and look like red algae may represent the earliest-known plants, a discovery that could force scientists to reassess the timing of when major lineages in the tree of life first appeared on Earth.

CAPE CANAVERAL, Fla. - Elon Musk's Space Exploration Technologies has won a GPS satellite launch contract over rival United Launch Alliance, a partnership of the top two U.S. aerospace companies Lockheed Martin Corp. and Boeing Co., the U.S. Air Force said on Tuesday.

See the rest here:
Newer type 2 diabetes drugs show heart protective quality in study - Reuters

Posted in Diabetes | Comments Off on Newer type 2 diabetes drugs show heart protective quality in study – Reuters

Nonprofit roundup: Courses on managing diabetes begin March 28 in Missoula – The Missoulian

Posted: March 19, 2017 at 4:40 pm

The Resource Center at Missoula Aging Services (MAS) is partnering with the MSU Extension Office and others to offer a six-week course for older adults with diabetes or pre-diabetes. The Diabetes Empowerment Education Program (DEEP) is available free to Medicare participants and their caregivers.

Classes will help people with diabetes learn how to take charge of their health and get control of the disease. While they are designed for older adults with Medicare, anyone with diabetes or pre-diabetes is welcome to attend. Courses will be held Tuesdays from 10 to 11:30 a.m., beginning Tuesday, March 28, and continuing through May 2, at the Missoula County Extension Office, 2825 Santa Fe Court.

Please call MAS at 406-728-7682 for more information or to register, or go to deepclasses.eventbrite.com to register online. Additional partners include Mountain-Pacific Quality Health, Everyone with Diabetes Counts (EDC), and the Montana Geriatric Education Center.

The YWCA Missoula invites you to LUNAFEST, a local event hosted by the GUTS! (Girls using their strengths) Program. GUTS! partners with LUNAFEST, an exciting national film festival featuring short films by, for and about women, to highlight the capacity, strength and beauty of women in film and young women of Missoula. This event will raise funds for our Summer Outdoor Adventure Trips and a smaller percentage for the Breast Cancer Fund. LUNAFEST will be held on Wednesday, April 19, at the Wilma Theater in downtown Missoula. Doors open for our silent auction at 6 p.m. and the show starts at 7 p.m. Tickets are $15 in advance, $18 day of show.

Child Care Resources training: Spring Conference is set for Saturday, April 1. How do we create rich environments that meet early childhood standards and allow children and their teachers to flourish?

As an active participant, sharing photos and discussing and brainstorming environmental successes and challenges in your child care program. Youll also create a design for one learning center that you can immediately begin to create in your program.

This conference will be held from 9 a.m. to 4 p.m. on Saturday, April, 1. This training is $25, and is worth six training hours.

Application workshops for anyone interested in applying to build a home in partnership with Habitat for Humanity of Missoula will be held Sunday, April 2, at 2 p.m. and Wednesday, April 5, at 7 p.m.

Workshops will be held in the conference room at the YWCA located at 1130 West Broadway.

No child care will be available at either meeting.

Applications will be available at the meetings. Access to our applications on our website or to pick up at our office will be available on Tuesday, April 4. Completed applications must be submitted by 5 p.m. on Friday, April 21.

Call 406-549-8210 for more information.

To help older adultswho want to get better control of their diabetes, Mountain-Pacific Quality Health, the Medicare Quality Innovation Network-Quality Improvement Organization (QIN-QIO) for Montana, Ag Worker Health & Services and the Montana Geriatric Education Center are partnering together to offer a series of six, free diabetes classes. These classes provide fun, informative and interactive ways to help people with diabetes or pre-diabetes (high blood sugar)

The classes support, not replace, professional diabetes self-management education. The classes are designed for people age 65 and older. Ag Worker Health & Services will make future announcements about any classes or events for those younger than 65.

The series kicks off Monday, April 17, from 5:30 to 6:30 p.m., at Ag Worker Health and Services at 9801 Valley Grove Drive #D, which is about a half mile north of Lolo on Highway 93. Classes will then meet every Monday through May 22. Anyone interested in attending theses classes can register by calling 406-273-4633.

Humanities Montana awarded a $900 grant to The Montana Racial Equity Project to support the Native American Race Relations and Healing Symposium. The day-long event will feature two panel discussions lead by authors, historians, language preservationists, and experts including John Robinson and Sterling HolyWhiteMountain. The first panel will focus on tribal sovereignty and the second will explore current issues facing the Native American population. The event will take place on Saturday, April 1, from 10 a.m. to 3 p.m., at the Native American Studies Building at the University of Montana.

Humanities Montana awarded a $1,000 grant to the Wedsworth Memorial Library to fund a monthly book discussion. Dr. Penny Hughes-Briant will host eight discussions from August 2017 to May 2018. All events will be held at the Wedsworth Memorial Library in Cascade.

Humanities Montana awarded a $1,000 grant to Columbus High School to fund the Yellowstone National Park Inquiry Project. Students will research and build projects on the impacts that visitors have on Yellowstone National Parks animals, ecosystem, environment, and cultural values.

Humanities Montana is the states independent, nonprofit state affiliate of the National Endowment for the Humanities.

Go here to see the original:
Nonprofit roundup: Courses on managing diabetes begin March 28 in Missoula - The Missoulian

Posted in Diabetes | Comments Off on Nonprofit roundup: Courses on managing diabetes begin March 28 in Missoula – The Missoulian

Page 1,636«..1020..1,6351,6361,6371,638..1,6501,660..»